National Black HIV/AIDS Awareness and Information Day -- February 7, 2005Statement of Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases, on National Black HIV/AIDS Awareness and Information Day
February 7, 2005 Today, February 7th, marks the fifth annual observance of National Black HIV/AIDS Awareness and Information Day -- part of a critical effort encouraging individuals to get tested, educated and involved in HIV research activities. The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, joins with national, regional and local HIV/AIDS groups in supporting this collaborative effort to raise awareness of HIV/AIDS among African Americans and to mobilize African-American communities to get involved. Although significant progress has been made in the fight against HIV/AIDS, the African-American community continues to be disproportionately affected by the epidemic. African Americans make up approximately 12 percent of the U.S. population, but account for approximately half of newly reported HIV infections. In the United States, HIV/AIDS has claimed the lives of more than 195,000 African Americans since the epidemic began. Globally, a large proportion of the estimated 39 million people living with HIV/AIDS are African or of African descent, as evidenced by the huge burden of disease in sub-Saharan Africa and the Caribbean. In recent years, an increasing number of African-American women and children are being affected by HIV/AIDS. In 2003, two-thirds of U.S. AIDS cases in both women and children were among African Americans. Despite the efforts of researchers, doctors, nurses, educators and communities across the world, an HIV vaccine still does not exist. However, NIAID remains firmly committed to the development of a safe and effective HIV vaccine, and many vaccine candidates are now being tested in clinical trials globally. Among many efforts, a large clinical trial testing a novel and promising HIV vaccine candidate began enrollment last month. This trial is a collaboration between Merck & Co. Inc and NIAID's multicenter HIV Vaccine Trials Network (HVTN). It is essential that diverse communities, including African Americans, volunteer for this trial and other HIV/AIDS clinical trials so that we can learn if drug regimens or vaccine candidates work for everyone. This clinical trial, among others supported by NIAID, needs a diverse cohort of participants to ensure that research findings will be credible, acceptable and relevant to all populations in the U.S. National Black HIV/AIDS Awareness and Information Day is an opportunity to educate our communities about research progress in the areas of prevention, care and treatment options, and the importance of research to find new treatment regimens, microbicides and vaccines. Ending the AIDS crisis among African Americans in this country requires collaborative efforts by everyone -- pharmaceutical companies, government institutions, universities, non-profit organizations, communities and individuals. I commend and support all those who have taken a leadership role in promoting HIV prevention education, treatment and care, as well as those who have volunteered for the clinical research studies that move us closer to a cure and a vaccine. We all have a role to play in the fight against HIV/AIDS, and I thank all those who are working to reduce the burden of this terrible scourge. Further information about National Black HIV/AIDS Awareness and Information Day is available at www.blackaidsday.org. Information on treatment and vaccine clinical trials is available at www.aidsinfo.nih.gov. Dr. Fauci is director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health in Bethesda, Maryland. This article was provided by U.S. National Institute of Allergy and Infectious Diseases.
|
|